TCG Crossover GP I, LLC 13D and 13G filings for AN2 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:44 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I, LLC | 0 0.000% | -1,555,118 (Position Closed) | Filing |
| 2024-11-13 4:25 pm Sale | 2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I, LLC | 1,555,118 5.200% | -1,123,091 (-41.93%) | Filing |
| 2024-02-09 4:29 pm Purchase | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I, LLC | 2,678,209 9.000% | 1,388,889 (+107.72%) | Filing |
| 2023-07-25 4:19 pm Purchase | 2023-06-26 | 13G | AN2 Therapeutics, Inc. ANTX | TCG Crossover GP I, LLC | 1,289,320 6.600% | 1,289,320 (New Position) | Filing |